Literature DB >> 16478815

Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport.

David J Handelsman1.   

Abstract

CONTEXT: The objective of the study was to review the rationale underlying the banning of human chorionic gonadotropin (hCG) and estrogen blockers (antiestrogens, specific estrogen receptor modulators, aromatase inhibitors) in sports for male and female athletes in the light of gender differences in regulation of reproductive physiology. EVIDENCE ACQUISITION: We reviewed well-controlled clinical studies of exogenous testosterone effects on human muscle size and strength in men and all available evidence relevant to the effects of hCG and estrogen blockers on blood testosterone in men and women. EVIDENCE SYNTHESIS: Well-designed placebo-controlled clinical studies in men with suppressed pituitary-testicular axis establish a strong case that, across a wide range from sub- to supraphysiological doses, muscle growth and strength is proportional to exogenous testosterone dose and resulting blood testosterone concentrations. In men, there is unequivocal evidence that hCG and estrogen blockers cause consistent and sustained rise in blood testosterone concentrations. In women, although there has been no direct testing of ergogenic or myotrophic properties of exogenous testosterone in healthy women, either hCG or estrogen blockers do not produce any consistent or biologically significant increase blood testosterone concentrations.
CONCLUSIONS: In men undergoing potential stimulation of endogenous blood testosterone concentrations, blood testosterone concentration is a reasonable surrogate measure for muscle growth and increased strength in men. Because hCG and estrogen blockers produce marked increase in blood testosterone concentration in men, this provides strong evidence to support the banning of hCG and estrogen blockers in men. In women, however, the negligible effect on blood testosterone suggests that drug-induced performance enhancement by hCG or estrogen blockers is highly unlikely. Furthermore, routine urinary hCG testing in young women risks invasion of privacy by detecting unrecognized pregnancy. These considerations suggest that prohibition of hCG and estrogen blockers should be restricted to men in which they are well justified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16478815     DOI: 10.1210/jc.2005-2569

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Diagnosis and Management of Anabolic Androgenic Steroid Use.

Authors:  Bradley D Anawalt
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

Review 2.  Gonadotropins in doping: pharmacological basis and detection of illicit use.

Authors:  U-H Stenman; K Hotakainen; H Alfthan
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

Review 3.  Indirect androgen doping by oestrogen blockade in sports.

Authors:  D J Handelsman
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 4.  Drug abuse in athletes.

Authors:  Claudia L Reardon; Shane Creado
Journal:  Subst Abuse Rehabil       Date:  2014-08-14

5.  Rapid determination of anti-estrogens by gas chromatography/mass spectrometry in urine: Method validation and application to real samples.

Authors:  E Gerace; A Salomone; G Abbadessa; S Racca; M Vincenti
Journal:  J Pharm Anal       Date:  2011-10-26

6.  Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products.

Authors:  Manuela Pellegrinia; Maria Concetta Rotolo; Francesco Paolo Busardò; Roberta Pacifici; Simona Pichini
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects.

Authors:  Jules A A C Heuberger; Adam F Cohen
Journal:  Sports Med       Date:  2019-04       Impact factor: 11.136

8.  Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine.

Authors:  Connie Luk; Samantha Jones; Claire Thomas; Nick C Fox; Tze H Mok; Simon Mead; John Collinge; Graham S Jackson
Journal:  JAMA Neurol       Date:  2016-12-01       Impact factor: 18.302

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.